Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 1816 clinical trials
PCOS Treatment Using DLBS3233 and Metformin.

This is a 3-arm, randomized, double-blind, double-dummy, and controlled clinical study over 6 months of treatment to evaluate the metabolic and clinical efficacy as well as the safety of DLBS3233 alone, metformin and combination of both, in improving metabolic and reproductive parameters.

  • 0 views
  • 23 Sep, 2022
  • 3 locations
TEST SITE

This is a 3-arm, randomized, double-blind, double-dummy, and controlled clinical study over 6 months of treatment to evaluate the metabolic and clinical efficacy as well as the safety of DLBS3233 alone, metformin and combination of both, in improving metabolic and reproductive parameters.

  • 0 views
  • 28 Sep, 2022
  • 3 locations
Study Site

This is a 3-arm, randomized, double-blind, double-dummy, and controlled clinical study over 6 months of treatment to evaluate the metabolic and clinical efficacy as well as the safety of DLBS3233 alone, metformin and combination of both, in improving metabolic and reproductive parameters.

  • 0 views
  • 28 Sep, 2022
Test

This is a 3-arm, randomized, double-blind, double-dummy, and controlled clinical study over 6 months of treatment to evaluate the metabolic and clinical efficacy as well as the safety of DLBS3233 alone, metformin and combination of both, in improving metabolic and reproductive parameters.

  • 0 views
  • 26 Sep, 2022
  • 3 locations
Study Test Site  

This is a 3-arm, randomized, double-blind, double-dummy, and controlled clinical study over 6 months of treatment to evaluate the metabolic and clinical efficacy as well as the safety of DLBS3233 alone, metformin and combination of both, in improving metabolic and reproductive parameters.

  • 0 views
  • 28 Sep, 2022
  • 2 locations
Learning Through Gamification in Higher Education

"Health care legislation, management and administration" is a basic subject offered in the physical therapy university degree. The juridical features of this subject usually provokes a lack of motivation between students. Although not commonly used in university teaching, gamification could provide further affordances for improving students' engagement which provokes better …

  • 0 views
  • 16 Feb, 2024
  • 1 location
Early Routine vs. Selective Human Milk Fortification in Extremely Preterm Infants

The aim of the project is to study the effects of fortification (using a Human Milk Donor Fortifier) of an exclusive preterm human milk diet on outcome of extremely preterm neonates, born at less or equal to 27 weeks.

enteral feeding
  • 0 views
  • 16 Feb, 2024
  • 1 location
Minocycline in MS: Confirmation of Benefit

This is an open-label, single-arm clinical trial. Trial participants will include men and women, aged 18-60 years who have had a first demyelinating event within the previous 180 days and who have brain magnetic resonance imaging (MRI) with at least two brain T2 lesions which are at least 3 mm …

mri brain
multiple symptoms
brain lesion
demyelination
minocycline
  • 0 views
  • 16 Feb, 2024
  • 1 location
Patient Preference of Apalutamide Versus Enzalutamide in Patients With Recurrent or Metastatic Hormone-Sensitive Prostate Cancer

This is a prospective, open-label, randomized, controlled, cross-over trial assessing patient preference for apalutamide versus enzalutamide in 146 male patients with recurrent or metastatic hormone-sensitive prostate cancer. The primary objective is to investigate whether there is any difference in patient preference between apalutamide and enzalutamide in patients with recurrent or …

adenocarcinoma of prostate
androgens
cancer
enzalutamide
antiandrogen therapy
  • 0 views
  • 16 Feb, 2024
  • 1 location
Study of Camrelizumab (SHR-1210) in Combination With Concurrent Chemoradiotherapy in Locally Advanced Esophageal Cancer

This is a randomised, double-blinded, placebo-controlled, multi-center phase III trial, comparing the efficacy and safety of treatment with Camrelizumab (SHR-1210) + definitive chemoradiotherapy(dCRT) vs placebo+dCRT for locally advanced esophageal cancer patients in China. Camrelizumab (SHR-1210) is a humanized anti-PD1 IgG4 monoclonal antibody.

monoclonal antibody therapy
cancer
antibody therapy
paclitaxel
monoclonal antibodies
  • 0 views
  • 16 Feb, 2024
  • 1 location